Form 4: ProPhase Labs Director Jason Barr Acquires 70,000 Stock Options
SEC Form 4
Director Jason Barr acquired 70,000 stock options in ProPhase Labs, Inc. on March 17, 2024.
Summary
- On March 17, 2024, Jason Barr, a director of ProPhase Labs, Inc., acquired 70,000 stock options.
- The exercise price of these options is $6.
- The options vest in four equal installments, starting September 30, 2024, and continuing through June 30, 2025, contingent upon continued service as a non-employee director.
- The options expire on March 17, 2031.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing detailing stock option grants. It's neutral in tone and reflects a routine corporate action. The sentiment is slightly positive as it indicates alignment of the director's interests with the company's performance.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Future Outlook
The vesting schedule is contingent upon Jason Barr's continued service as a non-employee director.
Industry Context
Stock option grants are a common form of compensation for directors and executives, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Option grants to board members are a common practice across publicly traded companies to incentivize performance and align interests with shareholders.
- The size and vesting schedule of the grant would need to be compared to similar companies in the same industry and of similar market capitalization to determine if it is within the typical range.
- Companies like Quest Diagnostics or Laboratory Corporation of America could be considered for benchmarking purposes, although specific compensation details for board members would need to be sourced from their respective filings.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to act in ways that benefit shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 03/17/2024 | Date of transaction: Jason Barr acquired 70,000 stock options. |
| 03/17/2024 | Date of grant: Jason Barr was granted the options with an exercise price of $6. |
| 09/30/2024 | First vesting date: 25% of the options vest. |
| 12/31/2024 | Second vesting date: Another 25% of the options vest. |
| 03/31/2025 | Third vesting date: Another 25% of the options vest. |
| 06/30/2025 | Final vesting date: The last 25% of the options vest. |
| 03/17/2031 | Expiration date: The options expire. |
| 03/19/2024 | Date of signature: Jason Barr signed the Form 4. |
Keywords
stock options, Form 4, director, ProPhase Labs, PRPH, Jason Barr, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.